ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/proteasome
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/proteasome
16
trial(s) found.
NCT06892522
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma (
2024-515770-27-00--M25-059
)
ABBV-383
Carfilzomib
Daratumumab
Dexamethasone
Lenalidomide
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cancer therapy,CD38-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,BCMA-targeting
immuno-oncology therapy,CD38-targeting
immunomodulatory imide drug
proteasome inhibitor
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06577025
Haem
Phase 2
Recruiting
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (
aMMbition
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT06413498
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma (
iMMagine-3
)
Bortezomib
Carfilzomib
Cyclophosphamide
Daratumumab
Dexamethasone
Fludarabine
Pomalidomide
alkylating agent
anti-CD38 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD38-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD38-targeting
immunomodulatory imide drug
proteasome inhibitor
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06208150
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide (
MonumenTAL-6
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
VIC
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
Bortezomib
Carfilzomib
Dexamethasone
Elotuzumab
Pomalidomide
Selinexor
XPO1 inhibitor
anti-CS1 monoclonal antibody
cancer therapy
cancer therapy,CS1-targeting
cancer therapy,XPO1-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,CS1-targeting
immunomodulatory imide drug
proteasome inhibitor
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06152575
Haem
Phase 3
Recruiting
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY (
MAGNETISMM-32--C1071032
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3066 - Epping - Northern Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05704049
Haem
Phase 2
Recruiting
A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) (
IZALCO
)
anti-CD38 monoclonal antibody
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3066 - Epping - Northern Hospital
NCT05572515
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (
MajesTEC-9
)
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT05552976
Haem
Phase 3
Recruiting
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-2
cereblon E3 ligase modulator
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.9016 - Dunedin - Dunedin Hospital
NCT04973605
Haem
Phase 1
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
2023-507751-30-00--BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
+ cancer therapy,proteasome-targeting
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
ACTRN12624001468516
Haem
Phase 2
Not yet recruiting
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (
Dara@Home
)
anti-CD38 monoclonal antibody
+ cancer therapy,proteasome-targeting
Multiple myeloma
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12621001458820
Haem
Phase 1
Not yet recruiting
Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib (
CHARMM
)
anti-malarial agent
proteasome inhibitor
Cancer
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (14)
Not yet recruiting (2)
Recruitment Country and State
VIC (14)
NSW (13)
WA (8)
QLD (7)
SA (5)
NZ (3)
TAS (1)
ACT (1)
Phase
Phase 1 (3)
Phase 2 (5)
Phase 3 (8)
Trial Type
Haem (15)
Paed (1)
Cancer Therapy Class
proteasome
100%
cereblon
69%
CD38
44%
BCMA
31%
GPRC5D
19%
CS1
19%
XPO1
13%
Bcl2
6%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
3004 - Melbourne, Southbank - Alfred Health (5)
3066 - Epping - Northern Hospital (5)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2170 - Liverpool - Liverpool Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2500 - Wollongong - Wollongong Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
2217 - Kogarah - St George Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2605 - Garran - The Canberra Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Acute lymphoblastic leukaemia
Leukaemia
Lymphoid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy